Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA
Derdelinckx, Judith (University Hospital Antwerp (Bèlgica))
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
De Laere, Maxime (University of Antwerp. Laboratory of Experimental Hematology)
Lee, Wai-Ping (University Hospital Antwerp (Bèlgica))
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Wens, Inez (University of Antwerp. Laboratory of Experimental Hematology)
Nkansah, Irene (University of Antwerp. Laboratory of Experimental Hematology)
Daans, Jasmijn (University of Antwerp. Laboratory of Experimental Hematology)
De Reu, Hans (University of Antwerp. Laboratory of Experimental Hematology)
Jolanta Keliris, Aneta (University of Antwerp. Bio-Imaging Lab)
Van Audekerke, Johan (University of Antwerp. Bio-Imaging Lab)
Vanreusel, Verdi (University of Antwerp. Bio-Imaging Lab)
Pieters, Zoë (University of Antwerp. Laboratory of Experimental Hematology)
Van Der Linden, Annemie (University of Antwerp. Bio-Imaging Lab)
Verhoye, Maraleen (University of Antwerp. Bio-Imaging Lab)
Molenberghs, Geert (L-BioStat. I-BioStat. KU Leuven)
Hens, Niel (University of Antwerp. Centre for Health Economics Research and Modelling Infectious Diseases)
Goossens, Herman (University of Antwerp. Laboratory of Medical Microbiology)
Willekens, Barbara (University Hospital Antwerp (Bèlgica))
Cras, Patrick (University of Antwerp. Born Bunge Institute)
Ponsaerts, Peter (University of Antwerp. Laboratory of Experimental Hematology)
Berneman, Zwi (University Hospital Antwerp (Bèlgica))
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cools, Nathalie (University Hospital Antwerp (Bèlgica))

Data:	2019
Resum:	Background: Although effective in reducing relapse rate and delaying progression, current therapies for multiple sclerosis (MS) do not completely halt disease progression. T cell autoimmunity to myelin antigens is considered one of the main mechanisms driving MS. It is characterized by autoreactivity to disease-initiating myelin antigen epitope(s), followed by a cascade of epitope spreading, which are both strongly patient-dependent. Targeting a variety of MS-associated antigens by myelin antigen-presenting tolerogenic dendritic cells (tolDC) is a promising treatment strategy to re-establish tolerance in MS. Electroporation with mRNA encoding myelin proteins is an innovative technique to load tolDC with the full spectrum of naturally processed myelin-derived epitopes. Methods: In this study, we generated murine tolDC presenting myelin oligodendrocyte glycoprotein (MOG) using mRNA electroporation and we assessed the efficacy of MOG mRNA-electroporated tolDC to dampen pathogenic T cell responses in experimental autoimmune encephalomyelitis (EAE). For this, MOG-immunized C57BL/6 mice were injected intravenously at days 13, 17, and 21 post-disease induction with 1α,25-dihydroxyvitamin D-treated tolDC electroporated with MOG-encoding mRNA. Mice were scored daily for signs of paralysis. At day 25, myelin reactivity was evaluated following restimulation of splenocytes with myelin-derived epitopes. Ex vivo magnetic resonance imaging (MRI) was performed to assess spinal cord inflammatory lesion load. Results: Treatment of MOG-immunized C57BL/6 mice with MOG mRNA-electroporated or MOG-pulsed tolDC led to a stabilization of the EAE clinical score from the first administration onwards, whereas it worsened in mice treated with non-antigen-loaded tolDC or with vehicle only. In addition, MOG-specific pro-inflammatory pathogenic T cell responses and myelin antigen epitope spreading were inhibited in the peripheral immune system of tolDC-treated mice. Finally, magnetic resonance imaging analysis of hyperintense spots along the spinal cord was in line with the clinical score. Conclusions: Electroporation with mRNA is an efficient and versatile tool to generate myelin-presenting tolDC that are capable to stabilize the clinical score in EAE. These results pave the way for further research into mRNA-electroporated tolDC treatment as a patient-tailored therapy for MS.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Messenger RNA electroporation ; Tolerogenic dendritic cells ; Antigen-specific treatment ; Experimental autoimmune encephalomyelitis ; Multiple sclerosis ; Tolerance induction
Publicat a:	Journal of neuroinflammation, Vol. 16 (August 2019) , art. 167, ISSN 1742-2094

DOI: 10.1186/s12974-019-1541-1
PMID: 31416452

20 p, 3.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats